AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T1 response with a diverse TCR repertoire.

AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus–vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 in clinical trials and real-world studies. We characterized CD4 and CD8 T cell responses induced by AZD1222 vaccination in peripheral blood mononuclear cells from 296 unique vaccine recipients aged 18 to 85 years who enrolled in the phase 2/3 COV002 trial. Total spike protein–specific CD4 T cell helper type 1 (T1) and CD8 T cell responses were increased in AZD1222-vaccinated adults of all ages after two doses of AZD1222. CD4 T2 responses after AZD1222 vaccination were not detected. Furthermore, AZD1222-specific T1 and CD8 T cells both displayed a high degree of polyfunctionality in all adult age groups. T cell receptor β (TCRβ) sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for both AZD1222-induced CD4 and CD8 T cell responses. Overall, AZD1222 vaccination induced a polyfunctional T1-dominated T cell response, with broad CD4 and CD8 T cell coverage across the SARS-CoV-2 spike protein.